The life sciences industry has increasingly tuned its attention to rare diseases, with 143 orphan drugs launched in the U.S. over the past five years,
accounting for 53% of the total 268 launches during this period. Despite the growing number of treatments, achieving launch excellence in rare disease market remains an intricate challenge. Traditional pharma product launch strategies used for broad market are often ineffective in this unique landscape. Innovative approaches are essential, and many organizations are harnessing the power of data and analytics to drive success and excellence at every stage of the launch journey.
